版本:
中国

BRIEF-Alkermes says FDA approves two-month ARISTADA for treatment of schizophrenia

June 6 Alkermes plc:

* FDA approves two-month ARISTADA® for treatment of schizophrenia

* New two-month dose is expected to be available in mid-June

* Says new two-month dose of ARISTADA is expected to be available in mid-June Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐